Why R&D innovation holds the key to greater patient impact
04 May 2023
How can innovation in clinical trials drive greater patient impact? BeiGene’s Dr Nils Eckardt and Dr Mieke Borgs highlight how novel systems and ways of working can support the delivery of high-quality medicines faster and more efficiently, helping to deliver greater and faster patient access in Europe.
Dual CRISPR therapy plus long-acting ART eliminates HIV in mice
03 May 2023
In a study published May 1 in Proceedings of the National Academy of Sciences, a research team led by scientists from the Lewis Katz School of Medicine at Temple University and the University of Nebraska Medical Center (UNMC) described how they used CRISPR to inactivate or snip out two different genes in HIV-infected humanized mice. By combining this approach with a long-acting form of antiretroviral therapy, the researchers were able to eliminate the virus in around 60% of the models—a big boost from the 29% they reported back in 2019
Pharma responds to proposed EU pharmaceutical legislation reform
02 May 2023
The European Commission’s (EC’s) reform of the EU pharmaceutical legislation published on 26 April 2023, adopted a proposal for a new Directive and a new Regulation. These amend and replace the existing general pharmaceutical legislation.
Global research consortium to help address antimicrobial resistance
02 May 2023
Researchers in the UK, South Africa, Uganda and Brazil have formed the Centres for Antimicrobial Optimisation Network (CAMO-Net) to optimise antimicrobial use globally.
Monoclonal antibody combination treatment given NICE approval
28 April 2023
Shown to increase myeloma remission times by more than two years, a combination treatment that uses a monoclonal antibody has been approved by NICE.
28 April 2023
The Ministry of Health of the Russian Federation has authorized the first Russian originator for the treatment of multiple sclerosis developed by the scientists of the biotechnology company BIOCAD. The medicinal product was given the trade name Ivlizi®. The launch of a Russian originator can significantly increase the efficacy of therapy and the patients’ quality of life.
Immunotherapy to become standard treatment for infants with ALL
27 April 2023
First-line immunotherapy blinatumomab significantly improved survival in babies with acute lymphoblastic leukaemia in an international trial.
Pharma within planetary boundaries
27 April 2023
Regulatory changes along a drug’s lifecycle should ensure that the health benefits of pharmaceuticals, which have a large ecological footprint, do not cost the environment. Dorothea Baltruks, Research Associate at the Centre for Planetary Health Policy, outlines how forthcoming EU pharmaceutical legislation could pave the way to solutions.
26 April 2023
In 2022, Prottermin, a drug for Parkinson’s disease developed in Novosibirsk Institute of Organic Chemistry named after N. N. Vorozhtsov (NIOH) of SB RAS, completed the first phase of clinical trials. The result turned out to be promising: the drug demonstrated high antiparkinsonian activity. Nevertheless, the second phase has not started for lack of funding, Interfax reports.
Interneuron cell therapy results in up to 94% seizure reduction in focal epilepsy
26 April 2023
Human GABAergic interneurons were implanted in two patients with drug-refractory focal epilepsy. Preliminary results show participants have experienced greater than 90% seizure reduction since surgery.
NovaMedica to localize in Russia one of the most popular anti-migraine drugs in the world
21 March 2023
Merry Christmas and Happy New Year!
27 December 2022
15 December 2022
In April 2023 drugs worth of 54.3 billion rubles were produced in Russia
09 June 2023
In Russia, child mortality is declining, while life expectancy is growing
09 June 2023
How can biopharma strengthen its resilience?
08 June 2023
Sergey Glagolev: Foreign companies are interested in conducting clinical trials in Russia
08 June 2023